-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256

Benzinga·08/11/2026 13:07:59
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $255 to $256.